SCOPUS 정보 검색 플랫폼

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 40, Issue 2, 2011, Pages 144-148

Cardiac safety of trastuzumab in adjuvant: A review across 53 observations;Tolérance cardiaque du trastuzumab en adjuvant : revue à travers 53 observations

(10) Tanz, R a,c Mahfoud, T a Bazine, A a Khmamouch, R a Bensouda, Y b Ismaili, N b Benjaafar, N b El Gueddari, B K b Ichou, M a Errihani, H b

a MILITARY HOSPITAL MOHAMMED V (Morocco)

b NATIONAL INSTITUTE OF ONCOLOGY (Morocco)

c NONE (Morocco)

Author keywords

Cardiac toxicity; Left ventricular ejection fraction; Trastuzumab

Indexed keywords

ANTHRACYCLINE; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CASE CONTROL STUDY; DRUG MONITORING; DRUG SAFETY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MOROCCO; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HEART DISEASES; HUMANS; MIDDLE AGED; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 79953029969 PISSN: 03682315 EISSN: None Source Type: Journal
DOI: 10.1016/j.jgyn.2010.12.003 Document Type: Article

Times cited : (2)

References (9)

1
- 0035869407
- Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2
- DOI 10.1056/NEJM200103153441101
- D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of Chemotherapy plus a Monoclonal Antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
- (2001) New England Journal of Medicine , vol.344 , Issue.11 , pp. 783-792
- Slamon, D.J.¹ Leyland-Jones, B.² Shak, S.³ Fuchs, H.⁴ Paton, V.⁵ Bajamonde, A.⁶ Fleming, T.⁷ Eiermann, W.⁸ Wolter, J.⁹ Pegram, M.¹⁰ Baselga, J.¹¹ Norton, L.¹²

2
- 37549062128
- Trastuzumab and cardiac toxicity: Monitoring in the adjuvant setting
- A. Saad, and J. Abraham Trastuzumab and cardiac toxicity: monitoring in the adjuvant setting Community Oncol 4 2007 739 744
- (2007) Community Oncol , vol.4 , pp. 739-744
- Saad, A.¹ Abraham, J.²

3
- 26844536978
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
- DOI 10.1056/NEJMoa052122
- E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684 (Pubitemid 41464706)
- (2005) New England Journal of Medicine , vol.353 , Issue.16 , pp. 1673-1684
- Romond, E.H.¹ Perez, E.A.² Bryant, J.³ Suman, V.J.⁴ Geyer Jr., C.E.⁵ Davidson, N.E.⁶ Tan-Chiu, E.⁷ Martino, S.⁸ Paik, S.⁹ Kaufman, P.A.¹⁰ Swain, S.M.¹¹ Pisansky, T.M.¹² Fehrenbacher, L.¹³ Kutteh, L.A.¹⁴ Vogel, V.G.¹⁵ Visscher, D.W.¹⁶ Yothers, G.¹⁷ Jenkins, R.B.¹⁸ Brown, A.M.¹⁹ Dakhil, S.R.²⁰ more..

4
- 26844503270
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
- DOI 10.1056/NEJMoa052306
- M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672 (Pubitemid 41464705)
- (2005) New England Journal of Medicine , vol.353 , Issue.16 , pp. 1659-1672
- Piccart-Gebhart, M.J.¹ Procter, M.² Leyland-Jones, B.³ Goldhirsch, A.⁴ Untch, M.⁵ Smith, I.⁶ Gianni, L.⁷ Baselga, J.⁸ Bell, R.⁹ Jackisch, C.¹⁰ Cameron, D.¹¹ Dowsett, M.¹² Barrios, C.H.¹³ Steger, G.¹⁴ Huang, C.-S.¹⁵ Andersson, M.¹⁶ Inbar, M.¹⁷ Lichinitser, M.¹⁸ Lang, I.¹⁹ Nitz, U.²⁰ more..

5
- 34548531901
- Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
- DOI 10.1200/JCO.2006.09.1611
- T. M. Suter, M. Procter, and D. J. van Veldhuisen Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant Trial JCO 25 2007 3859 3865 (Pubitemid 47477261)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.25 , pp. 3859-3865
- Suter, T.M.¹ Procter, M.² Van Veldhuisen, D.J.³ Muscholl, M.⁴ Bergh, J.⁵ Carlomagno, C.⁶ Perren, T.⁷ Passalacqua, R.⁸ Bighin, C.⁹ Klijn, J.G.M.¹⁰ Ageev, F.T.¹¹ Hitre, E.¹² Groetz, J.¹³ Iwata, H.¹⁴ Knap, M.¹⁵ Gnant, M.¹⁶ Muehlbauer, S.¹⁷ Spence, A.¹⁸ Gelber, R.D.¹⁹ Piccart-Gebhart, M.J.²⁰ more..

6
- 29744442709
- Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
- DOI 10.1200/JCO.2005.02.4091
- E. Tan-Chiu, G. Yothers, and E. Romond Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23 2005 7811 7819 (Pubitemid 46657378)
- (2005) Journal of Clinical Oncology , vol.23 , Issue.31 , pp. 7811-7819
- Tan-Chiu, E.¹ Yothers, G.² Romond, E.³ Geyer Jr., C.E.⁴ Ewer, M.⁵ Keefe, D.⁶ Shannon, R.P.⁷ Swain, S.M.⁸ Brown, A.⁹ Fehrenbacher, L.¹⁰ Vogel, V.G.¹¹ Seay, T.E.¹² Rastogi, P.¹³ Mamounas, E.P.¹⁴ Wolmark, N.¹⁵ Bryant, J.¹⁶

7
- 32144448027
- Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment
- DOI 10.1200/JCO.2005.13.300
- M.S. Ewer, M.T. Vooletich, and J.B. Durand Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 2005 7820 7826 (Pubitemid 46657379)
- (2005) Journal of Clinical Oncology , vol.23 , Issue.31 , pp. 7820-7826
- Ewer, M.S.¹ Vooletich, M.T.² Durand, J.-B.³ Woods, M.L.⁴ Davis, J.R.⁵ Valero, V.⁶ Lenihan, D.J.⁷

8
- 33748642331
- Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience
- DOI 10.1200/JCO.2005.04.9551
- V. Guarneri, D.J. Lenihan, and V. Valero Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center Experience J Clin Oncol 2006 10.1200/JCO.2005.04.9551 (Pubitemid 46622286)
- (2006) Journal of Clinical Oncology , vol.24 , Issue.25 , pp. 4107-4115
- Guarneri, V.¹ Lenihan, D.J.² Valero, V.³ Durand, J.-B.⁴ Broglio, K.⁵ Hess, K.R.⁶ Michaud, L.B.⁷ Gonzalez-Angulo, A.M.⁸ Hortobagyi, G.N.⁹ Esteva, F.J.¹⁰

9
- 36148961294
- Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
- E.A. Perez, E.H. Romond, and J. Suman Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer J Clin Oncol 25 2007 18S
- (2007) J Clin Oncol , vol.25
- Perez, E.A.¹ Romond, E.H.² Suman, J.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.